Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunovant Inc (IMVT)

Immunovant Inc (IMVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,015,596
  • Shares Outstanding, K 175,277
  • Annual Sales, $ 0 K
  • Annual Income, $ -413,840 K
  • EBIT $ -487 M
  • EBITDA $ -487 M
  • 60-Month Beta 0.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.62

Options Overview Details

View History
  • Implied Volatility 69.14% (-15.63%)
  • Historical Volatility 64.28%
  • IV Percentile 47%
  • IV Rank 19.14%
  • IV High 173.11% on 10/22/25
  • IV Low 44.52% on 03/27/25
  • Expected Move (DTE 13) 0.85 (3.72%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 93
  • Volume Avg (30-Day) 159
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 10,790
  • Open Int (30-Day) 12,972
  • Expected Range 21.99 to 23.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.72
  • Number of Estimates 10
  • High Estimate -0.57
  • Low Estimate -0.78
  • Prior Year -0.76
  • Growth Rate Est. (year over year) +5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.43 +6.58%
on 11/10/25
24.83 -8.01%
on 11/14/25
-0.76 (-3.22%)
since 11/05/25
3-Month
14.58 +56.65%
on 09/22/25
26.17 -12.72%
on 10/30/25
+5.70 (+33.26%)
since 09/05/25
52-Week
12.72 +79.56%
on 04/09/25
29.49 -22.55%
on 12/09/24
-5.56 (-19.58%)
since 12/05/24

Most Recent Stories

More News
Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Study in uncontrolled Graves’ disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment data IMVT-1402 development is progressing...

IMVT : 22.84 (-0.31%)
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business...

IMVT : 22.84 (-0.31%)
ROIV : 20.97 (-0.99%)
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

The law firm of Kahn Swick & Foti, LLC (“KSF”) has commenced an investigation into Immunovant , Inc. (NasdaqGS: IMVT) (“Immunovant”). KSF is investigating whether Immunovant’s...

IMVT : 22.84 (-0.31%)
Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

First-ever potentially disease-modifying therapy for uncontrolled Graves’ disease patients Of 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response,...

IMVT : 22.84 (-0.31%)
IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

NEW YORK and NEW ORLEANS , Aug. 29, 2025 /PRNewswire/ -- The law firm of Kahn Swick & Foti, LLC ("KSF") has commenced an investigation into Immunovant , Inc. (NasdaqGS: IMVT)...

IMVT : 22.84 (-0.31%)
IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immunovant, Inc. (“Immunovant” or “the Company”)...

IMVT : 22.84 (-0.31%)
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

The law firm of Kahn Swick & Foti, LLC (“KSF”) has commenced an investigation into Immunovant , Inc. (NasdaqGS: IMVT) (“Immunovant”). KSF is investigating whether Immunovant’s...

IMVT : 22.84 (-0.31%)
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus

Immunovant, Inc. IMVT reported first-quarter fiscal 2026 adjusted net loss of 60 cents per share, narrower than the Zacks Consensus Estimate of a loss of 69 cents. In the year-ago quarter, the company...

IMVT : 22.84 (-0.31%)
CRMD : 10.56 (-0.75%)
ALVO : 5.47 (+7.89%)
ZYME : 26.69 (+0.64%)
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

Initiated a second potentially registrational study of IMVT-1402 in Graves’ disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren’s disease (SjD), both in June 2025 All other...

IMVT : 22.84 (-0.31%)
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

IMVT : 22.84 (-0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing batoclimab, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The...

See More

Key Turning Points

3rd Resistance Point 23.65
2nd Resistance Point 23.39
1st Resistance Point 23.11
Last Price 22.84
1st Support Level 22.57
2nd Support Level 22.31
3rd Support Level 22.03

See More

52-Week High 29.49
Fibonacci 61.8% 23.08
Last Price 22.84
Fibonacci 50% 21.10
Fibonacci 38.2% 19.13
52-Week Low 12.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar